You are here

Article info

Article menu
Download PDFPDF
Respiratory infection
Original research
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19

Authors

  1. Correspondence to Dr Fasihul A Khan, Centre for Respiratory Research, University of Nottingham, Nottingham NG7 2RD, UK; fasihul.khan{at}nottingham.ac.uk
View Full Text

Citation

Khan FA, Stewart I, Fabbri L, et al
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19
Thorax 2021;76:907-919.

Publication history

  • Received May 11, 2020
  • Revised January 10, 2021
  • Accepted January 21, 2021
  • First published February 12, 2021.
Online issue publication 
February 19, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage